Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Gilead Sciences, Inc.. A complete text table follows the diagram.
The HIV franchise funds a broader liver-disease and oncology portfolio, converting $6.96 billion of quarterly revenue into $2.02 billion of net income
Swipe to explore
Biktarvy, Descovy, oncology and liver-disease sales are reported product subtotals. Remaining portfolio is the exact $1.215B residual to consolidated revenue and includes other HIV products, Veklury, other products, royalties and product-table rounding. The $6M net nonoperating expense is the exact operating-to-pretax bridge.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Biktarvy | 1 | $3.4B | 48.3% of total revenue |
| Descovy | 1 | $807M | HIV prevention and treatment |
| Oncology portfolio | 1 | $810M | Trodelvy, Yescarta and Tecartus |
| Liver-disease portfolio | 1 | $767M | Hepatitis and Livdelzi |
| Remaining portfolio | 1 | $1.2B | Other HIV, Veklury, other products and royalty |
| Total revenue | 2 | $7.0B | Biopharma product portfolio |
| Operating income | 3 | $2.6B | 37.2% operating margin |
| Product & innovation cost base | 3 | $4.4B | Reported total costs and expenses |
| Income before tax | 4 | $2.6B | After financing and other items |
| Net nonoperating expense | 4 | $6M | Interest offset by other income |
| Net income | 5 | $2.0B | 29.0% net margin |
| Income tax | 5 | $559M | 21.7% effective rate |
| From | To | Value |
|---|---|---|
| Biktarvy | Total revenue | $3.4B |
| Descovy | Total revenue | $807M |
| Oncology portfolio | Total revenue | $810M |
| Liver-disease portfolio | Total revenue | $767M |
| Remaining portfolio | Total revenue | $1.2B |
| Total revenue | Operating income | $2.6B |
| Total revenue | Product & innovation cost base | $4.4B |
| Operating income | Income before tax | $2.6B |
| Operating income | Net nonoperating expense | $6M |
| Income before tax | Net income | $2.0B |
| Income before tax | Income tax | $559M |